These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 2943606

  • 1. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A, Rosenn B, Palti Z, Ebstein B, Har-Nir R, Ron M.
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [Abstract] [Full Text] [Related]

  • 2. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI, Steingold KA, de Ziegler D, Lapolt PS, Chang RJ, Judd HL.
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [Abstract] [Full Text] [Related]

  • 3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 4. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

  • 5. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 6. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
    Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Fossati P.
    Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
    [Abstract] [Full Text] [Related]

  • 7. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M, Liz-Lestón J, Lado-Abeal J.
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [Abstract] [Full Text] [Related]

  • 9. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F, Hatala DA, Speroff L.
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [Abstract] [Full Text] [Related]

  • 10. Ovulation induction with pulsatile luteinizing hormone-releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: endocrine results.
    Burger CW, Hompes PG, Korsen TJ, Schoemaker J.
    Fertil Steril; 1989 Jan; 51(1):20-9. PubMed ID: 2491993
    [Abstract] [Full Text] [Related]

  • 11. Ovulation induction with pulsatile luteinizing releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: clinical results.
    Burger CW, Korsen TJ, Hompes PG, van Kessel H, Schoemaker J.
    Fertil Steril; 1986 Dec; 46(6):1045-54. PubMed ID: 3096792
    [Abstract] [Full Text] [Related]

  • 12. GnRH analog administration in patients with polycystic ovarian disease.
    Meden-Vrtovec H.
    Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
    [Abstract] [Full Text] [Related]

  • 13. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L, Koskinen P, Kaihola HL, Erkkola R, Irjala K, Ruutiainen K.
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [Abstract] [Full Text] [Related]

  • 14. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C, Martínez de Osaba MJ, Martínez S, Fortuny A.
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [Abstract] [Full Text] [Related]

  • 15. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
    Anttila L, Ding YQ, Ruutiainen K, Erkkola R, Irjala K, Huhtaniemi I.
    Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 17. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M, Flamigni C, Campaniello E, Valdiserri A, Ferrari P, Meriggiola MC, Michelacci L, Pareschi A.
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [Abstract] [Full Text] [Related]

  • 18. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM, Randolph JF, Kelch RP, Marshall JC.
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [Abstract] [Full Text] [Related]

  • 19. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R, Black VY, Knochenhauer ES, Hines GA, Boots LR.
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [Abstract] [Full Text] [Related]

  • 20. Increased frequency of pulsatile luteinizing hormone-releasing hormone administration selectively decreases follicle-stimulating hormone levels in men with idiopathic azoospermia.
    Gross KM, Matsumoto AM, Berger RE, Bremner WJ.
    Fertil Steril; 1986 Mar; 45(3):392-6. PubMed ID: 3081382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.